MRNA
BEARISH
$50.8
Live
Moderna, Inc. · NASDAQ
Target $43.75
(-13.9%)
$22.28
52W Range
$59.55
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$20.15B
P/E
N/A
ROE
-28.9%
Profit margin
-145.2%
Debt/Equity
0.15
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
50%
MRNA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key Strengths
Low debt with D/E ratio of 0.15
Key Risks
Low profit margin of -145.2%
Weak financial trend (Piotroski F-Score: 1/9)
Declining revenue (-29.8%)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
50
35
30
35
0
AI Verdict
MRNA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Low debt with D/E ratio of 0.15, Low profit margin of -145.2%, Weak financial trend (Piotroski F-Score: 1/9)
Confidence
10%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
- Revenue is contracting.
Past
30/100
Historical performance + price trend: Shares moved -61.7% over 5Y and +79.2% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -28.9%.
- Thin profit margins.
Health
35/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.15).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$50.8
Analyst Target
$43.75
Upside/Downside
-13.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MRNA and closest competitors.
Updated 2026-03-31
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MRNA
Moderna, Inc.
Primary
|
-61.7% | -66.9% | +79.2% | +96.7% | -3.9% | -1.1% |
|
EXAS
Exact Sciences Corp
Peer
|
-16.4% | +58.3% | +122.8% | +95.9% | +1.4% | +1.0% |
|
INCY
Incyte Corporation
Peer
|
+12.8% | +28.6% | +60.8% | +2.8% | +6.0% | -1.2% |
|
ROIV
Roivant Sciences Ltd.
Peer
|
+203.5% | +236.3% | +193.9% | +72.8% | +7.3% | +5.7% |
|
CNC
Centene Corporation
Peer
|
-26.9% | -36.9% | -26.9% | +31.2% | +35.9% | +13.6% |
MRN
Moderna, Inc.
Primary
5Y
-61.7%
3Y
-66.9%
1Y
+79.2%
6M
+96.7%
1M
-3.9%
1W
-1.1%
EXA
Exact Sciences Corp
Peer
5Y
-16.4%
3Y
+58.3%
1Y
+122.8%
6M
+95.9%
1M
+1.4%
1W
+1.0%
INC
Incyte Corporation
Peer
5Y
+12.8%
3Y
+28.6%
1Y
+60.8%
6M
+2.8%
1M
+6.0%
1W
-1.2%
ROI
Roivant Sciences Ltd.
Peer
5Y
+203.5%
3Y
+236.3%
1Y
+193.9%
6M
+72.8%
1M
+7.3%
1W
+5.7%
CNC
Centene Corporation
Peer
5Y
-26.9%
3Y
-36.9%
1Y
-26.9%
6M
+31.2%
1M
+35.9%
1W
+13.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-11.17
PEG Ratio
N/A
P/B Ratio
2.31
P/S Ratio
10.36
EV/Revenue
8.01
EV/EBITDA
-5.45
Market Cap
$20.15B
Profitability
Profit margins and return metrics
Profit Margin
-145.17%
Operating Margin
-126.4%
Gross Margin
-105.76%
ROE
-28.87%
ROA
-14.51%
Growth
Revenue and earnings growth rates
Revenue Growth
-29.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.15
Low debt
Current Ratio
3.29
Strong
Quick Ratio
3.06
Excellent
Cash/Share
$14.68
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.7B
Gross Margin
33.1%
Op. Margin
-126.8%
Net Margin
-122.2%
Total Assets
$12.3B
Liabilities
$3.7B
Equity
$8.7B
Debt/Equity
0.43x
Operating CF
$0.9B
CapEx
$-0.0B
Free Cash Flow
$0.9B
FCF Yield
96%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-13
$-2.11
+18.9% surprise
2025-11-06
$-0.51
+76.4% surprise
2025-08-01
$-2.13
+28.3% surprise
Healthcare Sector Comparison
Comparing MRNA against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-28.87%
This Stock
vs
-88.14%
Sector Avg
-67.2%
(Below Avg)
Profit Margin
-145.17%
This Stock
vs
-16.28%
Sector Avg
+791.7%
(Superior)
Debt to Equity
0.15
This Stock
vs
2.66
Sector Avg
-94.3%
(Less Debt)
Revenue Growth
-29.8%
This Stock
vs
124.04%
Sector Avg
-124.0%
(Slower)
Current Ratio
3.29
This Stock
vs
4.47
Sector Avg
-26.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MRNA
Moderna, Inc.
|
BEARISH | $20.15B | - | -28.9% | -145.2% | $50.8 | |
|
EXAS
Exact Sciences Corp
|
BEARISH | $20.03B | - | -8.7% | -6.4% | $104.91 | Compare |
|
INCY
Incyte Corporation
|
BULLISH | $19.05B | 14.93 | 29.9% | 25.0% | $95.72 | Compare |
|
ROIV
Roivant Sciences Ltd.
|
NEUTRAL | $21.35B | - | -19.1% | -% | $29.83 | Compare |
|
CNC
Centene Corporation
|
BEARISH | $21.39B | - | -28.7% | -3.8% | $43.5 | Compare |
MRNA
Moderna, Inc.
BEARISH
Mkt Cap
$20.1B
P/E
-
ROE
-28.9%
Price
$50.8
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | KLINGER SHANNON THYME | Officer | Stock Award | 11,797 | - |
| 2026-03-05 | MOCK JAMES M | Chief Financial Officer | Stock Award | 11,797 | - |
| 2026-03-02 | KLINGER SHANNON THYME | Officer | Option Exercise | 23,884 | $429,880 |
| 2026-03-02 | KLINGER SHANNON THYME | Officer | Sale | 13,885 | $726,047 |
| 2026-02-27 | MOCK JAMES M | Chief Financial Officer | Stock Award | 11,004 | - |
| 2026-02-27 | HOGE STEPHEN | President | Stock Award | 39,830 | - |
| 2026-02-23 | HOGE STEPHEN | President | Option Exercise | 160,009 | $3,064,172 |
| 2026-02-23 | HOGE STEPHEN | President | Sale | 160,009 | $7,814,840 |
| 2026-02-11 | BANCEL STEPHANE J | Chief Executive Officer | Stock Award | 11,271 | - |
| 2026-02-11 | MOCK JAMES M | Chief Financial Officer | Stock Award | 2,630 | - |
| 2026-02-11 | HOGE STEPHEN | President | Stock Award | 4,884 | - |
| 2026-02-11 | KLINGER SHANNON THYME | Officer | Stock Award | 2,630 | - |
| 2026-01-05 | MOCK JAMES M | Chief Financial Officer | Stock Award | 1,452 | - |
| 2025-12-11 | AFEYAN NOUBAR BOGHOS | Director | Option Exercise | 23,853 | $259,998 |
| 2025-12-11 | BANCEL STEPHANE J | Chief Executive Officer | Option Exercise | 688,073 | $7,499,996 |
KLINGER SHANNON THYME
Officer
2026-03-05
11,797 shares
MOCK JAMES M
Chief Financial Officer
2026-03-05
11,797 shares
KLINGER SHANNON THYME
Officer
2026-03-02
23,884 shares
·
$429,880
KLINGER SHANNON THYME
Officer
2026-03-02
13,885 shares
·
$726,047
MOCK JAMES M
Chief Financial Officer
2026-02-27
11,004 shares
HOGE STEPHEN
President
2026-02-27
39,830 shares
HOGE STEPHEN
President
2026-02-23
160,009 shares
·
$3,064,172
HOGE STEPHEN
President
2026-02-23
160,009 shares
·
$7,814,840
BANCEL STEPHANE J
Chief Executive Officer
2026-02-11
11,271 shares
MOCK JAMES M
Chief Financial Officer
2026-02-11
2,630 shares
HOGE STEPHEN
President
2026-02-11
4,884 shares
KLINGER SHANNON THYME
Officer
2026-02-11
2,630 shares
MOCK JAMES M
Chief Financial Officer
2026-01-05
1,452 shares
AFEYAN NOUBAR BOGHOS
Director
2025-12-11
23,853 shares
·
$259,998
BANCEL STEPHANE J
Chief Executive Officer
2025-12-11
688,073 shares
·
$7,499,996
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
20 analysts
Piper Sandler
2026-02-23
Overweight
Overweight
Goldman Sachs
2026-02-17
Neutral
Neutral
RBC Capital
2026-02-17
Sector Perform
Sector Perform
Evercore ISI Group
2026-02-17
In-Line
In-Line
Morgan Stanley
2025-12-12
Equal-Weight
Equal-Weight
Jefferies
2025-12-12
Hold
Piper Sandler
2025-11-21
Overweight
Overweight
RBC Capital
2025-11-21
Sector Perform
Sector Perform
Leerink Partners
2025-11-21
Underperform
Underperform
B of A Securities
2025-11-10
Underperform
Underperform
Past News Coverage
Recent headlines mentioning MRNA from our newsroom.
Newest → oldest
No matching news yet.